Pablo Maroto

9.8k total citations · 3 hit papers
164 papers, 3.9k citations indexed

About

Pablo Maroto is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Pablo Maroto has authored 164 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Pulmonary and Respiratory Medicine, 72 papers in Surgery and 51 papers in Oncology. Recurrent topics in Pablo Maroto's work include Renal cell carcinoma treatment (53 papers), Bladder and Urothelial Cancer Treatments (40 papers) and Prostate Cancer Treatment and Research (39 papers). Pablo Maroto is often cited by papers focused on Renal cell carcinoma treatment (53 papers), Bladder and Urothelial Cancer Treatments (40 papers) and Prostate Cancer Treatment and Research (39 papers). Pablo Maroto collaborates with scholars based in Spain, United Kingdom and United States. Pablo Maroto's co-authors include Joaquim Bellmunt, Begoña Mellado, Maria De Santis, Sandrine Marréaud, Richard Sylvester, J. Martijn Kerst, Iwona Skoneczna, Michael Leahy, Graham M. Mead and Ronald de Wit and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Pablo Maroto

155 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

2015 688 citations Robert J. Motzer, Thomas E. Hutson et al. The Lancet Oncology profile →
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

2011 523 citations Maria De Santis, Joaquim Bellmunt et al. Journal of Clinical Oncology profile →
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

2012 420 citations Pablo Maroto et al. European Journal of Cancer profile →

Peers

Countries citing papers authored by Pablo Maroto

Since Specialization

Citations

This map shows the geographic impact of Pablo Maroto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Maroto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Maroto more than expected).

Fields of papers citing papers by Pablo Maroto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo Maroto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Maroto. The network helps show where Pablo Maroto may publish in the future.

Co-authorship network of co-authors of Pablo Maroto

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Maroto. A scholar is included among the top collaborators of Pablo Maroto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo Maroto. Pablo Maroto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach 2025 ·Oncology Reviews ·A. Zapatero, Teresa Alonso‐Gordoa, (unknown), (unknown), (unknown), (unknown), (unknown), Ray Manneh Kopp, Ángel Borque‐Fernando, (unknown), Pablo Maroto	0
2	Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study 2024 ·European Urology Oncology ·Xavier García del Muro, D. Páez López-Bravo, (unknown), Pablo Maroto, Patrizia Giannatempo, Daniel Castellano, Miguel Ángel Climent, Begoña P. Valderrama, Alfonso Gómez de Liaño, (unknown), Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo-Cordero, Andrea Necchi	6
3	A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1 2024 ·Clinical Cancer Research ·Neeraj Agarwal, Daniel Castellano, Teresa Alonso‐Gordoa, Jóse Ángel Arranz Arija, Émeline Colomba, Gwénaëlle Gravis, Loı̈c Mourey, Stéphane Oudard, Aude Fléchon, (unknown), Pablo Maroto, Michael T. Schweizer, Enrique Gallardo, (unknown), Arjun Vasant Balar, Nadine Haddad, Adams K. Appiah, (unknown), Josep M. Piulats	6
4	A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer 2023 ·British Journal of Cancer ·Valentine M. Macaulay, Simon Lord, Syed A. Hussain, Pablo Maroto, Robert H. Jones, Miguel Ángel Climent, Natalie Cook, Chia‐Chi Lin, Shian‐Shiang Wang, Diletta Bianchini, Mark Bailey, (unknown), Thomas Bogenrieder, Johann S. de Bono	3
5	A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial 2022 ·European Journal of Cancer ·Miguel Ángel Climent, Albert Font, Ignacio Durán, Javier Puente, María José Méndez-Vidal, M.I. Sáez, (unknown), Jóse Ángel Arranz Arija, Aranzazu González del Alba, (unknown), María José Juan-Fita, Emilio Esteban, Teresa Alonso‐Gordoa, B. Mellado González, Pablo Maroto, Martín Lázaro-Quintela, (unknown), Begoña Pérez‐Valderrama, (unknown), Daniel Castellano	9
6	Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy 2021 ·Biomedicines ·Elisabet Cantó, Ó. Rodríguez Faba, Carlos Zamora, (unknown), (unknown), (unknown), Geòrgia Anguera, Alberto Breda, Pablo Maroto, Sílvia Vidal	2
7	SEOM clinical guidelines for the treatment of advanced prostate cancer (2020) 2021 ·Clinical & Translational Oncology ·Aranzazu González del Alba, María José Méndez-Vidal, (unknown), Elena Castro, José A. Martínez-Climent, Enrique Gallardo, Enrique González‐Billalabeitia, David Lorente, Pablo Maroto, (unknown)	21
8	Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome 2020 ·Modern Pathology ·Juan María Roldán‐Romero, María Santos, Javier Lanillos, Eduardo Caleiras, Geòrgia Anguera, Pablo Maroto, Jesús García-Donás, Guillermo de Velasco, Ángel M. Martínez‐Montes, Bruna Calsina, María Monteagudo, Rocío Letón, Luis J. Leandro‐García, Cristina Montero‐Conde, Alberto Cascón, Mercedes Robledo, Cristina Rodríguez‐Antona	34
9	SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018) 2018 ·Clinical & Translational Oncology ·Aranzazu González del Alba, Guillermo de Velasco, Núria Laínez, Pablo Maroto, Rafael Morales‐Barrera, José Muñoz-Langa, Begoña Pérez‐Valderrama, (unknown), (unknown), (unknown)	15
10	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis 2016 ·European Journal of Cancer ·Bernard Escudier, Vincent Molinié, Sergio Bracarda, Pablo Maroto, Cezary Szczylik, Paul Nathan, Sylvie Négrier, Claudia Weiß, Camillo Porta, Viktor Grünwald, Laurence Albigès	66
11	Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature 2015 ·BMC Urology ·Vicente Guillém, Miguel Ángel Climent, Javier Cassinello, Emilio Esteban, Daniel Castellano, J.L. González-Larriba, Pablo Maroto, Carlos Camps	1
12	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial breakdown → 2015 ·The Lancet Oncology ·Robert J. Motzer, Thomas E. Hutson, Hilary Glen, M. Dror Michaelson, Ana M. Molina, Timothy Eisen, Jacek Jassem, Jakub Żołnierek, Pablo Maroto, Begoña Mellado, Bohuslav Melichar, Jiří Tomášek, Alton B. Kremer, Hanjoo Kim, Karen Wood, Corina E. Dutcus, James Larkin	688
13	Cost Assessment of Metastatic and Non-Metastatic Castration-Resistant Prostate Cancer Patient-Management in Spain 2013 ·Value in Health ·Juan Moróte, J.M. Cózar, Ignacio Durán, (unknown), (unknown), Pablo Maroto, B. Miñana, E. Solsona, Itziar Oyagüez, (unknown), (unknown), L. Gutiérrez, Guy Hechmati	1
14	Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus 2011 ·Journal of Clinical Oncology ·Pablo Maroto, Gary R. Hudes, Janice P. Dutcher, Theodore F. Logan, Charles S. White, Mizue Krygowski, Maria Cincotta, Mark Shapiro, Ignacio Durán, Anna Berkenblit	83
15	Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity 2011 ·Annals of Oncology ·Joaquim Bellmunt, J.L. González-Larriba, Celia Prior, Pablo Maroto, Joan Carles, Daniel Castellano, Begoña Mellado, Enrique Gallardo, José Luis Perez‐Gracia, (unknown), (unknown), Joan Albanell, Alfonso Calvo	101
16	Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986 2009 ·Journal of Clinical Oncology ·Maria De Santis, Joaquim Bellmunt, Graham M. Mead, J. Martijn Kerst, Michael Leahy, Pablo Maroto, Iwona Skoneczna, Sandrine Marréaud, Ronald de Wit, Richard Sylvester	123
17	Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium 2006 ·Annals of Oncology ·Joaquim Bellmunt, Santiago Albiol, (unknown), (unknown), Pablo Maroto	25
18	Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study 2005 ·Journal of Clinical Oncology ·Jorge Aparicio, J.R. Germà, Xavier García del Muro, Pablo Maroto, José Ángel Arranz, A. Sáenz, Agustín Barnadas, Joan Dorca, Josep Gumà, David Olmos, R. Bastús, Joan Carles, D. Almenar, M.A. Sánchez-Granero, Luis Paz‐Ares, (unknown), Begoña Mellado, A. Balil, M. López-Brea, (unknown)	134
19	Percepción de control y supervivencia en pacientes con cáncer de pulmón avanzado sometidos a tratamiento paliativo 2003 ·Ansiedad y Estrés ·Antoni Sanz, Pablo Maroto, Antoni Font, Eduardo Doval, Tomás Blasco Blasco, Cinta Pallarés, (unknown)	1
20	Fungal Infections in Patients with Solid Tumors Treated with High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation 2001 ·European Journal of Clinical Microbiology & Infectious Diseases ·J. Montesinos, C. Solà, Pablo Maroto, Ramón Salazar, Judith Balmañà, (unknown), Beatriz Pardo, R. Pericás, M. Gurguí, José López‐López	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact